Henney Nominated for FDA Commissioner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

Dr. Henney, a cancer specialist, has served in government under every president since Jimmy Carter. She was the FDA’s deputy commissioner for operations from 1992 to 1994.

Her nomination won warm praise from many in the medical and public health fields, including Health and Human Services Secretary Donna E. Shalala, PhD. The Secretary called Dr. Henney "a talented manager" with "the solid medical and academic credentials that are needed to understand the burgeoning field of biomedical research."

However, several conservative Republicans have indicated their opposition to Dr. Henney. They want to know specifically if she had anything to do with the FDA’s decision to allow testing of the abortion drug RU-486.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content